Mesenchymal stem cell therapy for meniscal repair - Mesoblast
Alternative Names: Chondrogen; OTI-030Latest Information Update: 02 Oct 2021
At a glance
- Originator Osiris Therapeutics
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cartilage replacements; Cell replacements; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Meniscus disorders; Osteoarthritis
Most Recent Events
- 16 Sep 2015 No recent reports on development identified - Phase-II for Meniscus disorders in USA (Intra-articular)
- 16 Sep 2015 No recent reports on development identified - Phase-II for Osteoarthritis (Prevention) in USA (Intra-articular)
- 14 Oct 2013 Mesoblast acquires Osiris Therapeutics' culture-expanded mesenchymal stem cell business